# To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

> **NCT06147518** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 240 (estimated)

## Conditions studied

- Compensated Cirrhosis
- Decompensated Cirrhosis

## Interventions

- **DRUG:** Metformin
- **DRUG:** Sitagliptin
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT06147518
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-20
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06147518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06147518, "To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06147518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*